Event Summary
Across discussions with clinical teams, a clear pattern is emerging. Many recruitment and execution challenges originate in early protocol decisions, where endpoints, eligibility, assessments, and operational demands are not fully aligned. These gaps often become the source of delays and amendment cycles later in the study.
AI is helping address this by reviewing protocol structure at the drafting stage and identifying risks that traditional processes miss. This gives teams a clearer view of feasibility and operational impact before activation.
Key Points Shaping Trial Design for 2026
Early identification of design risks is becoming essential for predictable timelines
AI supported reviews help align scientific goals with operational reality
Stronger feasibility signals lead to smoother activation and clearer recruitment expectations
Data driven site selection improves planning and readiness
Integrated protocol and feasibility insights reduce uncertainty across the development cycle
Featured Speakers
Rohit Banga
Co-Founder & CTO, Kitsa
- •18+ years building clinical and AI systems
- •Led a global CRO for 9 years
- •Former Senior Consultant, AWS Healthcare & Life Sciences
Franziska Stemmler
CEO, Hemex AG
- •25+ years in clinical operations and leadership
- •Expert in trial execution and organizational excellence
- •Advisor across global biotech and medtech ecosystems